Using nucleotide sequencing-based genotyping, we conducted a case-control study to examine cervical cancer risk associated with human papillomavirus (HPV) infection in a Japanese population. A consensus primer pair was used to amplify DNA from the L1 region of HPV by polymerase chain reaction (PCR). By PCR, 311 of 356 patients with cervical cancer and 333 of 3249 control individuals were positive for HPV. By the direct sequencing of PCR products, nucleotide sequences of 30 genotypes were obtained. A high incidence of type 52 and a low incidence of type 16 were characteristic of the control group. Odds ratios were estimated for 18 genotypes. Types 71, 90, and 91, previously uncharacterized, were classified as low-risk genotypes, which is consistent with predictions made on the basis of phylogeny. The present study is the first large case-control study of its kind to use nucleotide sequencing-based genotyping. employed in epidemiological studies have limited ability to detect HPV. In the majority of current studies, the L1 region of HPV DNA is amplified by polymerase chain reaction (PCR) with consensus primers [5] , and the PCR products are subjected to further analysis by hybridization with genotype-specific probes [5] . Our previous method was to first test for the presence of HPV by L1-primer PCR and then to distinguish HPV genotypes by E1-primer PCR. The L1 primers were designed by Yoshikawa et al. [6] , who have described their own PCRbased approach (PCR followed by a restriction enzyme fragment polymorphism analysis); the E1 primers were designed by us [7] [8] [9] . However, none of these methodologies can detect all genotypes [5] [6] [7] [8] [9] . To overcome this limitation, we decided to determine the nucleotide sequences of all L1 PCR products; in principle, this approach can detect all genotypes. Another reason for the lack of information about the cervical cancer risk associated with uncommon HPV genotypes is that previous case-control studies have included insufficient numbers of control individuals. Even the largest pooled study conducted to date [3] included !2000 control individuals. Here we report the results of the first large case-control study of its kind that uses nucleotide sequencing-based genotyping and that includes 13000 control individuals. The present study provides, for the first time, information on the cervical cancer risks associated with a number of HPV genotypes.
employed in epidemiological studies have limited ability to detect HPV. In the majority of current studies, the L1 region of HPV DNA is amplified by polymerase chain reaction (PCR) with consensus primers [5] , and the PCR products are subjected to further analysis by hybridization with genotype-specific probes [5] . Our previous method was to first test for the presence of HPV by L1-primer PCR and then to distinguish HPV genotypes by E1-primer PCR. The L1 primers were designed by Yoshikawa et al. [6] , who have described their own PCRbased approach (PCR followed by a restriction enzyme fragment polymorphism analysis); the E1 primers were designed by us [7] [8] [9] . However, none of these methodologies can detect all genotypes [5] [6] [7] [8] [9] . To overcome this limitation, we decided to determine the nucleotide sequences of all L1 PCR products; in principle, this approach can detect all genotypes. Another reason for the lack of information about the cervical cancer risk associated with uncommon HPV genotypes is that previous case-control studies have included insufficient numbers of control individuals. Even the largest pooled study conducted to date [3] included !2000 control individuals. Here we report the results of the first large case-control study of its kind that uses nucleotide sequencing-based genotyping and that includes 13000 control individuals. The present study provides, for the first time, information on the cervical cancer risks associated with a number of HPV genotypes.
Patients, materials, and methods. All study participants were residents of Okinawa prefecture, which lies apart from the main islands of Japan and has a population of 1.35 million people. In Okinawa, Ryukyu University Hospital operates a prefecture-wide cervical cancer registry and treats 190% of the patients living in the prefecture who have invasive cervical cancer.
Cervical swab samples were obtained from women who consulted Ryukyu University Hospital during 1993-2000. Consent was obtained for testing for HPV. To test for HPV, the cervical swab samples were subjected to DNA extraction, and the DNA was subjected to PCR using an L1 consensus primer pair (L1C1 and L1C2; reported by Yoshikawa et al. [6] ), as described elsewhere [7] . PCR with a b-globin primer pair was performed in parallel, and b-globin-negative samples were not included in further analyses. The L1 PCR products obtained from HPVpositive samples were stored frozen. The present study included only previously untreated patients who subsequently received histological diagnoses of invasive squamous cell carcinoma. were negative for HPV ( ) and control individuals who were negative for n p 45 HPV ( ) were used as reference categories. n p 2916 b L1 regions of these genotypes are not amplified by the MY09/MY11 primers [10] . years, 9.8%; у80 years, 5.9%]), there were 311 (87.4%; age range, 24-89 years; average age, 54.4 years) who were positive for HPV.
Control individuals included both women who had consulted Ryukyu University Hospital and the participants in cervical cancer screenings conducted in Okinawa during 1993-1995. The screenings were held in a number of locations so that women from most regions of the prefecture could participate. Cervical swab samples were subjected to HPV testing as described above, with the approval of city governments and of the Okinawa General Health Service Association, which conducted the screenings. The association provided us only with information on ages and cytology of the participating women. Women with no cytological abnormalities (Papanicolaou class I or II, with no koilocytosis) were regarded as control individuals, and their L1 PCR products were stored frozen. For nucleotide sequencing, stored L1 PCR products were thawed and subjected to electrophoresis on 2.5% agarose gel containing ethidium bromide. The bands (∼250-260 bp) were excised from the gel, and DNA was extracted and purified by use of the QIAquick Gel Extraction Kit (Qiagen). To prepare the sequencing templates, purified DNA was subjected to a second PCR, with the following modified consensus primers: L1C1B (5 -CCCGGGATCCCGTAAACGTTTTCCCTATTTT-TTT-3 ) and L1C2B (5 -CCCGCTGCAGTACCCTAAATACTC-TGTATTG-3 ). These primers contained original L1C1 and L1C2 primer sequences plus an additional 10 nt (indicated above by underscoring), to facilitate direct sequencing. This secondary PCR reaction (100 mL) contained ∼20 ng of template DNA, 50 pmol of each primer, 200 mmol of each dNTP/L, and 2 U of ExTaq polymerase (TaKaRa). Thermal-cycling conditions were as follows: initial denaturation at 94ЊC for 2 min; 20 cycles of denaturation at 94ЊC for 1 min, annealing at 52ЊC for 30 s, and extension at 70ЊC for 1 min; and final extension at 70ЊC for 5 min. The PCR products were gel purified as described above.
For sequencing reactions by use of a BigDye Terminator Kit (Applied Biosystems), ∼5 ng of the gel-purified secondary PCR products were used as templates. The original L1C1 and L1C2 primers were used for the sequencing of the templates directly on both strands. With the aid of the 10 terminal base pairs that had been added to the templates by the secondary PCR, these primers annealed stably to the templates and performed well in sequence reactions. Sequences of the region between the 2 primers were obtained by use of the ABI PRISM 310 Genetic Analyzer (Applied Biosystems). The similarity between the obtained L1 sequences and those of various HPV genotypes in the GenBank database was determined by BLAST analysis (http://www.ncbi.nlm.nih.gov/BLAST).
The x 2 test was used to compare the prevalence of different genotypes. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the cervical cancer risks associated with individual genotypes. NOTE. High-risk genotypes include those with ORs у5.0 and 95% CIs у3.0 and those detected in some patients with cervical cancer but in no control individuals [3] ; low-risk genotypes include those with ORs у1.0 and 95% CIs !3.0 and those detected in some control individuals but in no patients with cervical cancer [3] ; genotypes of undetermined risk include those either not tested for or not detected by genotype-specific probes in the study conducted by Muñ oz et al. [3] and genotypes not detected by nucleotide sequencing in the present study. CI, confidence interval; OR, odds ratio.
a Genotype-specific probes not reported. b Genotype 89 appeared as "CP6108" in the study by Muñ oz et al.
Results.
Nucleotide sequences corresponding to 30 HPV genotypes were detected (table 1); in patients with cervical cancer, 20 genotypes were detected as single-infecting genotypes. Common genotypes detected (those found in у3.0% of the patients who were positive for HPV) were types 16 (42.4%), 33 (9.0%), 58 (8.0%), 18 (7.7%), 52 (7.1%), 31 (6.1%), and 35 (4.2%). Our findings on common genotypes were similar to those of other studies [2] [3] [4] , except for type 45, which was nearly absent (0.3%) in the present study. However, consistent with the results of present study, the reported prevalence of type 45 was 0.7% and 1.2% in other studies conducted in Japanese populations, whereas the Asian average and the world average are 4.5% and 3.9%, respectively [4] . In control individuals, 28 genotypes were detected; common genotypes were types 52 (12.0%), 51 (8.4%), 35 (8.1%), 53 (5.7%), 56 (5.4%), 16 (4.8%), 68 (4.8%), 33 (3.6%), 90 (3.6%), 91 (3.6%), and 71 (3.0%). Types 52 and 51 were much more prevalent in our study than in other studies, in which type 16 was the most prevalent [2, 3] ; in our study, type 16 was much less prevalent than types 52 ( ) and 51 ( ). With respect to cer-P ! .001 P ! .05 vical cancer risk, the ORs of types 16 and 18 were very high (534.6 and 259.2, respectively); other genotypes with ORs 1100 were types 58, 33, and 31.
Nucleotide sequencing-based genotyping allowed us to assess the prevalence of and cervical cancer risks associated with genotypes that have not been detected by other methodologies. For instance, the prevalence of and risks associated with types 90 and 91 have not been reported previously. In the present study, both of these genotypes were found in 12 (3.6%) of the 333 control individuals who were positive for HPV but in only 1 (0.3%) of the 311 patients with cervical cancer who were positive for HPV. For both genotypes, ORs were 5.4 and the lower 95% CIs were 0.7; thus, they were both classified as lowrisk genotypes. Consistent with our epidemiological classifications, types 90 and 91 have been predicted, on the basis of phylogeny, to be low-risk genotypes [10] . Table 2 summarizes our study in comparison with a recent, large case-control study by Muñoz et al. [3] . The latter investigation pooled data from 11 studies conducted in 9 countries and included 1918 patients with cervical cancer (1739 of whom were positive for HPV) and 1928 control individuals (259 of whom were positive for HPV). Muñoz et al. estimated ORs and 95% CIs for 15 genotypes; we estimated ORs and 95% CIs for 18 genotypes. To facilitate comparison, the criteria used by Muñoz et al. for the classification of HPV genotypes were applied to our data. Both studies agreed on 16 high-risk genotypes and 5 low-risk genotypes. Discrepancy existed with regard to 2 genotypes. One was type 70, which was classified as a lowrisk genotype by Muñoz et al. but as a high-risk genotype by us. Consistent with our epidemiological classification, type 70 has been predicted, on the basis of phylogeny, to be a highrisk genotype [11] . The other discrepancy was with regard to type 39, which was classified as a high-risk genotype by Muñoz et al. but as a low-risk genotype by us. This genotype also has been predicted, on the basis of phylogeny, to be a high-risk genotype [11] .
The present study characterized 7 genotypes that were not tested for by Muñoz et al. (table 2) . These include types 71 and 84, in addition to the above-mentioned types 90 and 91. Risk information on type 71 has not been reported previously. In the present study, type 71 was found in 10 (3.0%) of the 333 control individuals who were positive for HPV but in 0 of the 311 patients with cervical cancer who were positive for HPV and, therefore, was classified as a low-risk genotype. Similarly, type 84 is likely a low-risk genotype, since it was found in 5 (1.5%) of the 333 control individuals who were positive for HPV but in 0 of the 311 patients with cervical cancer who were positive for HPV. Both types 71 and 84 have been predicted, on the basis of phylogeny, to be low-risk genotypes [10] .
Discussion. To our knowledge, the present study is the first large case-control study in which HPV genotyping has been based completely on nucleotide sequencing. The advantage that this approach has over others became evident when it allowed us to estimate the cervical cancer risks associated with previously uncharacterized genotypes. We characterized 7 genotypes that were not tested for by Muñoz et al. [3] . For 4 of these 7 genotypes (types 32, 86, 90, and 91), no genotype-specific probes have been reported to date. In conjunction with the large number of control individuals included in the present study, the nucleotide-sequencing approach allowed us to classify, for the first time, types 71, 90, and 91 as low-risk genotypes, and these classifications are consistent with predictions that have been made on the basis of phylogeny.
Reports on types 71, 90, and 91 are scarce. Type 71 was found in 1 case of grade I vaginal intraepithelial neoplasia (VAIN I) of 71 VAIN I-III cases and in 1 case of grade I cervical intraepithelial neoplasia (CIN I) of 386 CIN I-III cases [12] . Type 71 was also found in 7 of 3863 women (average age, 28 years) with no history of high-grade cervical disease [13] . Type 90 was found in 1 case with condylomatous change of the cervix and in 1 individual with normal cytology; type 91 also was found in 1 case with condylomatous change of the cervix and in 1 individual with normal cytology [10] .
When genotyping samples that are singly infected, the nucleotide-sequencing approach is free from ambiguous or false results. The only limitation would come from the sensitivity and detection spectrum of the L1 consensus primer pair used. The L1 consensus primer pair used in the present study performs well in detecting various HPV genotypes in clinical samples [14] ; this primer pair detects a broad spectrum of genotypes, including types 6, 11, 16, 18, 30, 31, 33-35, 39, 42-45, 51-56, 58, 59, 61, 66, 68, and 70 [6, 15] . In addition, it detects types 32, 67, 71-73, 82, 84, 86, 90, and 91, as shown here.
When genotyping samples that are multiply infected, the nucleotide-sequencing approach may not detect some coinfecting genotypes. A coinfecting genotype with a low number of copies could be masked by another coinfecting genotype with a much higher number of copies. On the other hand, hybridization-based approaches also may not detect some coinfecting genotypes. For instance, such types as 90 and 91, when coinfecting with other genotypes, must have gone undetected in previous studies, given that no specific probes for these genotypes have ever been used.
Multiply infected samples used in the present study are most likely included in the "not determined" (ND) category (table  1) . In ND samples, sequencing reactions proceeded efficiently and multiple sequence traces were superimposed. Similar data were obtained when 2 or 3 non-ND samples were artificially mixed. In the present study, ND samples were found in 4.8% of patients with cervical cancer who were positive for HPV and in 15.9% of control individuals who were positive for HPV (table 1) . These incidences are comparable to those which Muñoz et al. [3] reported for multiply infected samples. They observed multiple infection in 8.1% of patients with cervical cancer who were positive for HPV and in 13.9% of control individuals who were positive for HPV. One cannot rule out the possibility that our ND samples contained non-HPV DNA that was coamplified with HPV DNA. However, this is unlikely, because the likelihood of amplification of non-HPV DNA is very small. To date, we have found non-HPV sequences in only 2 samples, which were not included in the present study.
